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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: The rifampicin resistance of Mycobacterium tuberculosis is caused by
mutations in the 81-base pair region of the rpoB gene encoding the b-subunit of RNA poly-
merase. Sequences of the rpoB gene of 68 isolates were analyzed to identify the mutations
and to compare the mutations with their related susceptibilities.
Methods: Susceptibility tests of 68M. tuberculosis isolates, collected in Taiwan during the period
from 1999 to 2011, were performed by themodified agar proportion method according to Clinical
and Laboratory Standards Institute recommendations. Sequences of the rpoB gene and the
resistance profiles were analyzed and compared with the data from different geographic regions.
Results: Seven alleles were identified. Among 47 isolates of allele 1 (without mutations of rpoB),
46 were rifampicin-susceptible. The other 21 isolates (alleles 2 to 7, withmutations of rpoB) were
rifampicin-resistant, including 18 isolates that were multidrug-resistant. Five mutated alleles
demonstrated a single mutation. The mutations occurred in the codons 531 (68.2%), 513
(9.1%), 533 (9.1%), 516 (4.5%), and 526 (4.5%). The sensitivity and specificity of rpoB mutations
for predicting the rifampicin-resistance of M. tuberculosis were 95.5% and 100%, respectively.
Conclusion: The most prevalent mutations of the rpoB gene were missense mutations in the crit-
ical codons, encoding Ser-531, Gln-513, Leu-533, Asp-516, and His-526. Thesemutations had high
sensitivity and specificity for predicting the rifampicin-resistance ofM. tuberculosis isolates. The
resistance profiles and the frequencies of mutated codons of the rpoB gene varied in differentfectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, 160 Section
Taiwan.
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rpoB mutations of M. tuberculosis 267geographic regions, indicating that resistance evolved under the selective pressure of the ther-
apeutic regimens and the spread of different genetic clones.
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Multidrug resistance in Mycobacterium tuberculosis is
a global burden.1 According to a report from World Health
Organization,1 there were an estimated 8.8 million incident
cases of tuberculosis (TB) (range, 8.5 millione9.2 million)
globally in 2010, 1.1 million deaths (range, 0.9 millione1.2
million) among human immunodeficiency (HIV)-negative
cases of TB, and an additional 0.35 million deaths (range,
0.32 millione0.39 million) among people who were HIV-
positive. There were an estimated 12.0 million prevalent
cases (range, 11.0 millione14.0 million) of TB in 2010. In
2010, there were an estimated 650,000 cases of multidrug-
resistant TB (MDR-TB) among the world’s 12.0 million
prevalent cases of TB. Among the estimated 8.8 million new
and recurrent cases of TB in 2010, 5.7 million were diag-
nosed and reported to national TB control programs; among
notified cases, there were an estimated 290,000 cases of
MDR-TB, of which only 53,000 patients (18%) were reported
to have been diagnosed with the condition and enrolled on
appropriate treatment. According to the Taiwan Tubercu-
losis Control Report 2011,2 the annual incident cases of TB
were 13,237 (57.2 per 100,000 population) in 2010, and the
estimated rates of MDR-TB among new cases and previously
treated cases were 1.1% and 8.2% in 2009, respectively.
From a study conducted by a northern Taiwanese medical
center during the period from 2003 to 2004, the estimated
primary resistance patterns for 486 patients were 5.4% for
isoniazid, 0.4% for rifampicin, 0.4% for ethambutol, 0.8% for
streptomycin, and 8.0% for pyrazinamide).3 The resistance
of the M. tuberculosis complex to rifampicin is caused by
mutations in the 81 base pair (bp) region of the rpoB gene
encoding the b-subunit of RNA polymerase.4e6 The
frequency of codon mutations of rpoB in rifampicin-
resistant M. tuberculosis isolates varied in different
geographic regions. The sequence analysis of rpoB of 37
isolates from Italy demonstrated mutations in codons 531
(59.4%), 526 (35.1%), and 516 (8.1%).7 The data of 86
isolates from China showed mutations in codons 531
(41.0%), 526 (40.0%), 516 (4.0%), 513 (2.0%), and 533
(2.0%).8 The analysis of prevalence of rpoB mutations was
conducted by two reports in Taiwan in the past decade.9,10
Further surveillance is clearly needed to detect the evolu-
tion of mutations and associated resistance.
In this study, M. tuberculosis isolates, including rifam-
picin-resistant and rifampicin-susceptible isolates collected
in Taiwan during the period from 1990 to 2011, were tested
for susceptibility to rifampicin by the modified agar propor-
tion method according to the Clinical and Laboratory Stan-
dards Institute (CLSI) recommendations.11 Sequences of
their rpoB genes and resistance profiles were analyzed and
compared with the mutations among different geographic
regions.Materials and methods
Collection of M. tuberculosis isolates
Sixty-eight M. tuberculosis isolates were collected for this
study, including 39 isolates from Taichung Veterans General
Hospital (TCVGH), a medical center in central Taiwan; 25
isolates from 8 hospitals in northern Taiwan and 4 isolates
from 1 hospital in southern Taiwan during the period from
1999 to 2011. The sources of specimens included sputum
(60, 88.2%), cerebrospinal fluid (5, 7.4%), pleural effusion
(2, 2.9%) and abscess (1, 1.5%).Susceptibility test
The antimycobacterial susceptibility tests were performed
according to the CLSI M24-A2 modified agar proportion
method.11 The procedure is performed by inoculating equal
quantities of 100 and 10,000 dilutions of a standardized
inoculum (0.5e1 McFarland) onto 7H10 agar medium
(Bio Star, Taichung, Taiwan) with and without the test drug
and then incubating them at 35C, 10% CO2 for 21 days. The
number of colony-forming units growing on the drug-
containing medium compared with those growing on the
drug-free medium are then determined and expressed as
a percentage. Resistance is defined as growth on drug-
containing agar is greater than 1% of the number of colonies
that grow on the drug-free agar. The concentrations of
antituberculosis drugs were as follows: isoniazid 0.2 mg/mL,
streptomycin 2.0 mg/mL, rifampicin 1.0 mg/mL, and
ethambutol 5.0 mg/mL. Multidrug resistance was defined as
isolates resistant to at least isoniazid and rifampicin.11DNA sequencing
The DNA was extracted by 10 mg/mL of proteinase K and 5%
Tween 20 in 200 mM TRIS-HCl solution (pH 8.3) at 60C
overnight. The polymerase chain reaction (PCR) was per-
formed in a GeneAmp PCR System 9600 (Perkin-Elmer,
Norwalk, CT, USA) using the primer pair 5’-TCGAATATCTGG
TCCGCTTG-3’；3’-ACACGATCTCGTCGCTAAC-5’. The PCR
began with an initial 4-minute denaturation at 94C, fol-
lowed by 35 cycles of denaturation at 95C for 1 minute,
annealing at 55C for 2 minute, and extension at 72C for 2
minute, and finally an extension step at 72C for 5 minute.
The sequence reactions were performed by adding fluo-
rescent terminators (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA) and the primers used in the initial
PCR. The sequences were determined with an ABI PRISM
310 and 3100 automated DNA sequencer (Perkin-Elmer
Applied Biosystems).
Table 1 Mutations of rpoB and resistance profiles
Allelesa Codon and amino acid change No. of isolates Resistance profiles (n)
Allele 1 No mutation 47 susceptible to 4 drugs:(27); RifþSM:(1); EMB:(2);
INH:(9); INHþEMB:(3); INHþEMBþSM:(5)
Allele 2 531 TCG(Ser)/TTG(Leu) 14 INHþRifþSM:(8); INHþRif:(4); Rif:(2)
Allele 3 526 CAC(His)/TGC(Cys) 1 INHþRifþSM:(1)
Allele 4 516 GAC(Asp)/GTC(Val) 1 INHþRifþSM:(1)
Allele 5 531 TCG(Ser)/TGG(Try) 1 INHþRif:(1)
Allele 6 533 CTG(Leu)/CCG(Pro) 2 INHþRifþSMþEMB:(1); Rif:(1)
Allele 7 513 CAA(Gln)/AAA(Lys) 2 INHþRif: (2)
a The GenBank accession numbers of alleles 1 to 7 are AY155355 to AY155361. Allele 1 is identical to the reference sequence, L27989.
EMB Z ethambutol; INH Z isoniazid; RIF Z rifampicin; SM Z streptomycin.
268 Y.-H. Lin et al.The sequences obtained from all 68 isolates were
compared and each different sequence was assigned
a unique allele number.Results
The mutations of the rpoB gene and the resistance profiles
are listed in Table 1. Seven alleles were identified. The
GenBank sequence database accession numbers of the
seven alleles were AY155355 to AY155361. Allele 1 repre-
sented the original sequence without mutation, and alleles
2 to 7 demonstrated mutated sequences. Forty-seven
isolates were assigned as allele 1, including 27 isolates
susceptible to isoniazid, rifampicin, ethambutol, and
streptomycin; one isolate resistant to rifampicin and
streptomycin; and 19 isolates with other resistance profiles.
Five mutated alleles (alleles 2, 4, 5, 6, 7) possessed a single
mutation in the 81-bp hot region. The mutations occurred
in codons 531 (63.6%, TCG/TTG; 4.5%, TCG/TGG), 513
(9.1%, CAA/AAA), 533 (9.1%, CTG/CCG), 516 (4.5%,
GAC/GTC), and 526 (4.5%, CAC/TGC). Among the 21
isolates of alleles 2 to 7, 18 isolates were multidrug-
resistant; two isolates of allele 2 and one isolate of allele
6 were resistant to rifampicin only. The sensitivity and
specificity of rpoB mutations for predicting the rifampicin-
resistance of the M. tuberculosis complex were 95.5% and
100%, respectively.
The comparison of the frequency of codon mutations in
rifampicin-resistant isolates from different geographic
regions is listed in Table 2. The frequency of mutations,Table 2 Frequency of rpoB mutations in rifampicin-resistant M
Country (reference; no. of isolates)
508 511 513 5
Italy (7; n Z 37) 0 2.7 0
India (13; n Z 44) 2.2 6.8 2.2
East Asia (12; n Z 66) 0 0 6.0 1
China (8; n Z 86) 0 2.0 2.0
Kaohsiung, Taiwan (9; n Z 63) 0 1.9 0 1
Taipei, Taiwan (10; n Z 162) 0.6 0.0 4.9
This study (n Z 22) 0 0 9.1e.g., codons 531 (41.0%-63.6%), 513 (0%-6.0%), 533 (0%-
7.5%), 526 (10.5%- 40.0 %), and 516 (4.0%-16.7%) varied in
different geographic regions.7e10,12,13Discussion
In this study, no novel mutation was detected beyond the 23
mutations described in previous studies.10,14 The most
common mutations were missense mutations at codons 531
(Ser/Leu; Ser/Try), 513 (Gln/Lys), 533 (Leu/Pro), 516
(Asp/Val), and 526 (His/Cys). This finding is comparable to
the results of previous studies for isolates from the United
States,15 Europe,7 Asian countries,8,12,13,16 and Taiwan.9,10
The frequency of mutations varied in different geographic
regions, such as codons 531 (41.0 % in China,8 to 63.6% in
India13), 513 (0% in Italy7 and Kaohsiung, Taiwan,9 to 6.0% in
East Asia12), 533 (0% in Italy7 to 7.5% in Kaohsing, Taiwan9),
516 (4.0% in China8 to 16.7% in East Asia12), and 526 (10.5% in
East Asia12 to 40.0% in China8). The sequence analysis of rpoB
in 162 MDR-TB isolates, from Taipei (located in northern
Taiwan) during the period from 1998 to 2003, showed muta-
tion in codons531 (49.4%), 526 (20.4%), 516 (8.6%), 513 (4.9%),
and533 (3.7%).10 Themost commonmutationsof 53 (84.1%)of
63 rifampicin-resistant M. tuberculosis isolates, from Kaosh-
iung (located in southernTaiwan) during the period from1996
to 1998 were at codons 531 (41.5%), 526 (18.9%), 516 (15.1%),
and 533 (7.5%).9 In this study, codon 531 accounted for 68.2%
of mutations, higher than previously reported results in the
world. It could be due to the spread of a prevalent clone or
sampling bias due to a small number of isolates. The limited. tuberculosis isolates from different geographic regions
Frequency (%) of mutated codon
16 522 526 531 533 No mutation within
hot-spot region
8.1 0 35.1 59.4 0 0
4.5 0 22.7 63.6 2.2 2.2
6.7 0 10.5 51.5 3.0 10.5
4.0 3.0 40.0 41.0 2.0 10.0
5.1 1.9 18.9 41.5 7.5 15.9
8.6 2.4 20.4 49.4 3.7 9.9
4.5 0 4.5 68.2 9.1 4.5
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in different geographic regions and the high sensitivity and
specificity of the rpoB gene mutation for predicting rifam-
picin-resistance, indicate that molecular diagnostic tech-
niques (such as the microarray,17e19 and the Xpert MTB/RIF
test20e22) are powerful and reliable methods for detection of
rifampicin-resistant or multidrug-resistant isolates.
Mutations at different codons of rpoB could be associated
with different levels of rifampicin resistance. The mutation
at codon 531 or 526was associatedwith high-level resistance
to rifampicin (minimum inhibitory concentration
[MIC] > 64 mg/mL)14,23,24 and high-level cross-resistance to
all rifamycins, whereas mutation at codon 516 was associ-
ated with medium-level resistance to rifampicin
(MICZ 32mg/mL), but susceptibility to rifabutin.14 However,
some isolates withmutation at codon 516 or 533 in Indiawere
shown to have high-level resistance to rifampicin
(MIC > 128 mg/mL).13 Although the MIC tests were not per-
formed in this study, multidrug resistance appeared to be
prevalent in all the mutated alleles in this study.11,23
In earlier studies, strains with the same rpoB genotype
but from different geographic areas had similar patterns of
drug resistance.14,23 In contrast, the 14 isolates of allele 2
demonstrated three different resistance profiles in this
study. The resistance profiles could evolve by the selective
pressure of therapeutic regimens over a period of time in
different geographic regions.12
One isolate of allele 1, without mutation in the 81-bp
region, was resistant to rifampicin. Although resistance to
rifampicin is mostly mediated by mutations located in the
81-bp region of rpoB,mutations outside this region could be
found occasionally to be associated with resistance to
rifampin. Examples were mutations at codon 176
(GTC/TTC),25 codon 381 (GCG/GTG),26 codon 572 (ATC
to TTC),27,28 and codon 490 (CAG to CAT).16,29 Another
possible mechanism of rifampicin resistance could be due
to efflux pumps.30,31
In conclusion, the most prevalent mutations of the rpoB
gene were missense mutations at the critical codons,
encoding Ser-531, Gln-513, Leu-533, Asp-516, and His-526.
These mutations had high sensitivity and specificity for
predicting the rifampicin resistance of M. tuberculosis
isolates. The resistance profiles and the frequencies of
mutated codons of the rpoB gene, which varied in different
geographic regions, indicate that resistance profiles
evolved under the selective pressure of the therapeutic
regimens and the spread of different genetic clones.
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